CN113332425A - 聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用 - Google Patents
聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用 Download PDFInfo
- Publication number
- CN113332425A CN113332425A CN202110368694.4A CN202110368694A CN113332425A CN 113332425 A CN113332425 A CN 113332425A CN 202110368694 A CN202110368694 A CN 202110368694A CN 113332425 A CN113332425 A CN 113332425A
- Authority
- CN
- China
- Prior art keywords
- manganese dioxide
- preparation
- application
- microspheres
- polydopamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Inorganic materials O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 239000004005 microsphere Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 229940124350 antibacterial drug Drugs 0.000 title claims abstract description 18
- 241000588724 Escherichia coli Species 0.000 claims abstract description 14
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 12
- 241000894006 Bacteria Species 0.000 claims abstract description 11
- 239000000243 solution Substances 0.000 claims description 16
- 230000001580 bacterial effect Effects 0.000 claims description 12
- 239000002077 nanosphere Substances 0.000 claims description 9
- 230000005855 radiation Effects 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 239000002953 phosphate buffered saline Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 230000001678 irradiating effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000005286 illumination Methods 0.000 abstract description 9
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 229920001690 polydopamine Polymers 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 238000001878 scanning electron micrograph Methods 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960001149 dopamine hydrochloride Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000012221 photothermal agent Substances 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种聚多巴胺‑二氧化锰纳米微球在制备抗菌药物中的应用，属于抗菌材料的应用技术领域。聚多巴胺‑二氧化锰纳米微球在制备抗菌药物中的应用对大肠杆菌或金黄葡萄球菌有很好的抑制效果，在近红外光照射条件下，细菌可全部杀死。本发明所制备的聚多巴胺‑二氧化锰纳米微球无近红外光照条件下展示良好的生物相容性，当有近红外光照条件下，细菌被快速杀死。
Description
技术领域
本发明属于抗菌材料的应用技术领域，具体涉及聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用。
背景技术
在现代医学尚未形成的年代，人类的寿命往往很低，而传染病与伤口感染则是危害人类生命的两大元凶。人们常常惊讶于是什么导致仅仅一个小伤口就可能对人类生命造成致命的威胁，这直到列文虎克发明了显微镜后，人类才慢慢搞清楚这是细菌在作祟。
纳米抗菌材料是近些年被广泛研究的一类具有抑菌性能的新型材料，具有高比表面积、高反应活性和细菌的低对抗性。对细菌、真菌、酵母菌、藻类以及病毒等都具有良好的杀灭作用。
发明内容
针对现有技术中存在的问题，本发明要解决的技术问题在于提供聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用。
为了解决上述问题，本发明所采用的技术方案如下：
聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用。
所述聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用，所述细菌为大肠杆菌或金黄葡萄球菌。
所述聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用，将聚多巴胺-二氧化锰纳米微球与大肠杆菌或金黄葡萄球菌混合，设定温度为37℃，培养24小时；然后再用近红外光照射0~10min。
所述聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用，具体步骤如下：
（1）将金黄色葡萄球菌或大肠杆菌的单个菌落分别接种到无菌液体LB培养基中，将细菌悬液在恒温培养摇床中以每分钟180 转的速度孵育一夜；
（2）使用无菌磷酸盐缓冲盐水将细菌稀释为1×106 CFU/mL，用聚多巴胺-二氧化锰纳米微球配制成2 mg/m L的混悬液；
（3）将200μL细菌溶液和20μL聚多巴胺-二氧化锰纳米微球震荡摇匀，对细菌样品施加近红外辐射。
所述聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用，所述近红外光波长为808nm，辐射功率为1W。
所述聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用，照射时间为10min，每5min摇动一次。
有益效果：与现有的技术相比，本发明的优点包括：
本发明所制备的聚多巴胺-二氧化锰纳米微球无近红外光照条件下展示良好的生物相容性，当有近红外光照条件下，细菌被快速杀死。
附图说明
图1为实施例1制备的聚多巴胺-二氧化锰纳米微球的扫描电子显微镜照片图；
图2为808nm近红外光照600s后大肠杆菌的扫描电子显微镜照片图；
图3为808nm近红外光照600s后金黄葡萄球菌发热扫描电子显微镜照片图；
图4为808nm近红外光照600s后细菌细胞的荧光图像。
具体实施方式
为使本发明的上述目的、特征和优点能够更加明显易懂，下面结合具体实施例对本发明的具体实施方式做详细的说明。
实施例1
1、吸附剂聚多巴胺纳米微球的制备
将40mL的乙醇（C2H5OH）溶液中加入2mL的氢氧化铵（NH4OH）溶液，用90mL去离子水配置成混合物，在室温下搅拌0.5h。称取0.5g多巴胺盐酸盐，用10mL去离子水溶解配制成溶液添加至上述混合液中，随后将溶液搅拌1天。将反应后溶液离心得到黑色沉淀，超声去离子水洗涤三次，放入鼓风干燥箱中干燥24h得到聚多巴胺纳米微球。
2、吸附剂聚多巴胺-二氧化锰纳米微球的制备
称取0.13g的聚多巴胺纳米微球，用45mL去离子水溶解配置成溶液，用盐酸将pH调整至1，随后超声15min。将12.5mL的0.05mol·L-1高锰酸钾（KMnO4）溶液加入至聚多巴胺纳米微球溶液中，磁力搅拌器下反应4h，离心得到黑色沉淀，放入鼓风干燥箱中干燥24h。图1为实施例1制备的聚多巴胺-二氧化锰纳米微球的扫描电子显微镜照片图；聚多巴胺-二氧化锰纳米微球无近红外光照条件下展示良好的生物相容性。
对上述合成的光热剂聚多巴胺-二氧化锰纳米微球与大肠杆菌或金黄葡萄球菌，设定温度为37℃，培养24小时；然后再用近红外光(808nm)对培养的溶液照射0-10分钟，通过DAPI和PI荧光分析活/死细菌。
具体步骤如下：
（1）将耐药的金黄色葡萄球菌和大肠杆菌的单个菌落分别接种到50mL的无菌液体LB 培养基中，将耐药菌悬液在37°C的恒温培养摇床中以每分钟180 转的速度孵育一夜；
（2）使用无菌磷酸盐缓冲盐水(PBS)将细菌稀释为1×106 CFU/mL，用聚多巴胺-二氧化锰纳米微球配制成2 mg/m L的混悬液；
（3）将200μL上述细菌溶液和 20μL聚多巴胺-二氧化锰纳米微球震荡摇匀作为实验组，使用 PBS 作为空白对照组，对细菌样品施加或不施加近红外辐射，照射时间为10分钟，每5分钟摇动一次。辐射功率为1W，波长808nm，每组平行三次。
（4）反应后溶液加入500μL无菌水高速离心洗涤菌液后留下沉淀，加水稀释至500μL。然后用200μL DAPI(12.5 μg/m L)和PI (1.25 μg/mL)染色15 min，室温避光放置30min后，取10μL溶液用于激光扫描荧光共聚焦显微镜成像。
图2为808nm近红外光照600s后，大肠杆菌的SEM图片，两端破裂说明大肠杆菌在光热条件下死亡。图3为808nm近红外光照600s后，金黄葡萄球菌的SEM图片，两端破裂说明金黄葡萄球菌在光热条件下死亡。图4为808nm近红外光照600s后，大肠杆菌染色后的荧光显微镜照片，红色说明大肠杆菌全部死亡。
Claims (6)
1.聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用。
2.根据权利要求1所述聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用，其特征在于，所述细菌为大肠杆菌或金黄葡萄球菌。
3.根据权利要求1所述聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用，其特征在于，将聚多巴胺-二氧化锰纳米微球与大肠杆菌或金黄葡萄球菌混合，设定温度为37℃，培养24小时；然后再用近红外光照射0~10min。
4.根据权利要求1所述聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用，其特征在于，具体步骤如下：
（1）将金黄色葡萄球菌或大肠杆菌的单个菌落分别接种到无菌液体LB培养基中，将细菌悬液在恒温培养摇床中以每分钟180 转的速度孵育一夜；
（2）使用无菌磷酸盐缓冲盐水将细菌稀释为1×106 CFU/mL，用聚多巴胺-二氧化锰纳米微球配制成2 mg/m L的混悬液；
（3）将200μL细菌溶液和20μL聚多巴胺-二氧化锰纳米微球震荡摇匀，对细菌样品施加近红外辐射。
5.根据权利要求1~4任一所述聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用，其特征在于，所述近红外光波长为808nm，辐射功率为1W。
6.根据权利要求1~4任一所述聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用，其特征在于，照射时间为10min，每5min摇动一次。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110368694.4A CN113332425A (zh) | 2021-04-06 | 2021-04-06 | 聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用 |
| CN202310367086.0A CN116115752A (zh) | 2021-04-06 | 2021-04-06 | 聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110368694.4A CN113332425A (zh) | 2021-04-06 | 2021-04-06 | 聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310367086.0A Division CN116115752A (zh) | 2021-04-06 | 2021-04-06 | 聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113332425A true CN113332425A (zh) | 2021-09-03 |
Family
ID=77467864
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110368694.4A Pending CN113332425A (zh) | 2021-04-06 | 2021-04-06 | 聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用 |
| CN202310367086.0A Withdrawn CN116115752A (zh) | 2021-04-06 | 2021-04-06 | 聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310367086.0A Withdrawn CN116115752A (zh) | 2021-04-06 | 2021-04-06 | 聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN113332425A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114522249A (zh) * | 2022-03-01 | 2022-05-24 | 苏州大学 | 一种含锰涂层磷酸钙微球的制备方法及其在药物载体方面的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112023903A (zh) * | 2020-09-18 | 2020-12-04 | 南京林业大学 | 一种吸附阳离子染料污染物的无机纳米粒子修饰的聚多巴胺纳米微球及其制备方法 |
-
2021
- 2021-04-06 CN CN202110368694.4A patent/CN113332425A/zh active Pending
- 2021-04-06 CN CN202310367086.0A patent/CN116115752A/zh not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112023903A (zh) * | 2020-09-18 | 2020-12-04 | 南京林业大学 | 一种吸附阳离子染料污染物的无机纳米粒子修饰的聚多巴胺纳米微球及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| NAVEEN CHANDRA JOSHI 等: "Biological Synthesis, Characterisations and Antimicrobial activities of manganese dioxide (MnO2) nanoparticles", 《RESEARCH J. PHARM. AND TECH.》 * |
| YU FU 等: "Polydopamine antibacterial materials", 《MATERIALS HORIZONS》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114522249A (zh) * | 2022-03-01 | 2022-05-24 | 苏州大学 | 一种含锰涂层磷酸钙微球的制备方法及其在药物载体方面的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116115752A (zh) | 2023-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yan et al. | pH switchable nanoplatform for in vivo persistent luminescence imaging and precise photothermal therapy of bacterial infection | |
| Gao et al. | Beer yeast-derived fluorescent carbon dots for photoinduced bactericidal functions and multicolor imaging of bacteria | |
| CN112795202B (zh) | 具有抗菌功能的mof复合材料及其制备方法和应用 | |
| CN113018417B (zh) | 一种促伤口愈合抑菌药物材料及其制备方法 | |
| CN114306382B (zh) | 一种铜基纳米酶及其制备方法和应用 | |
| CN113234436B (zh) | 一种近红外碳量子点/二氧化硅复合材料及其制备方法和应用 | |
| CN112056310B (zh) | 一种dfns负载碳量子点/二硫化钼量子点及其制备方法和应用 | |
| CN112899808B (zh) | 一种多功能纳米纤维及其制备方法与应用 | |
| CN114887060A (zh) | 一种近红外碳点/二硫化钼复合材料及其应用 | |
| CN113332425A (zh) | 聚多巴胺-二氧化锰纳米微球在制备抗菌药物中的应用 | |
| CN111170292B (zh) | 一种纤维相红磷纳米粒子的制备方法及其应用 | |
| CN110051837A (zh) | 一种CuO/ZnO/Au纳米粒子及其制备方法和应用 | |
| CN106424753A (zh) | 一种MnO2‑Ag纳米复合材料的制备及其应用 | |
| CN112021333A (zh) | 一种光敏抗菌材料的制备方法 | |
| Liu et al. | Construction of a matchstick-shaped Au@ ZnO@ SiO 2–ICG Janus nanomotor for light-triggered synergistic antibacterial therapy | |
| CN114699387B (zh) | 一种核壳结构的载药纳米颗粒及其制备方法和应用 | |
| CN109481678B (zh) | 一种有机无机杂化的复合银纳米颗粒及其制备方法和应用 | |
| US20160059033A1 (en) | Method for Killing and Tracing Bacteria by Coating Same with Self-Assembled Gold Nanoshell Layer and Producing Photothermal Decomposition and Cold Light by means of Laser | |
| CN113289013B (zh) | PDA-MnO2薄膜及其制备方法和应用 | |
| CN112618716A (zh) | 一种光动力联合溶菌酶抗菌方法 | |
| CN116216719A (zh) | 复合纳米材料及制备方法、纳米纤维支架及应用 | |
| CN114261957B (zh) | 一种含硫碳纳米点的制备方法 | |
| CN113332424A (zh) | 光热剂PACP-MnO2纳米微球在制备抗菌药物中的应用 | |
| CN115606606A (zh) | 新型金属多酚网络负载金属氧化物抗菌纳米粒子、制备方法及应用 | |
| CN113287607A (zh) | 光热剂PACP-MnO2薄膜及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210903 |
|
| RJ01 | Rejection of invention patent application after publication |